Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

View:
Post by Ingiboy on Aug 05, 2022 2:06pm

NR's

The 3 NR's from this past week show progress in locking down patents for Dermaprecise as well as showing the market that the injection device is getting closer to submission for FDA and CE Mark Approval,  I would have thought that it would have spiked the share price a little with some reasonable volume but as usual that is not the case.  We are basically up $.01 from the all-time low share price with minimal volume.  It is hard to speculate what the management of the company thought would happen to the share price after releasing these NR's.  I think they are always optomistic but I am sure disappointed.   It looks like the only thing that will boost the share price is a judgement in favour of Replicel in the Shiseido Arbitration and the Dermaprecise FDA Approval application is submitted.

If both of these happen then we begin to guess as to what the affect will be on the share price.

 A positive result from the arbitration could come in many forms and all will have a different affect on the share price.  The best  scenario is Shiseido is forced to compensate Replicel.  The amount will have a direct correlation on the boost to the share price.  Also if Replicel wins and Shiseido plans to press forward with bringing RCH-01 to market in Asia under a new arrangement with Replicel, Replicel's global potential for the product could be huge.

Once Dermaprecise is granted FDA Approval and eventually CE Mark Approval it will be interesting to see how the Dermal Industry adopts usage of the device.  If the Industry enthusiastically buys the device we should should see a good bost to the share price.

O.K. now for the speculation on the share price if both of these above scenarios have a positve outcome.   Without being too unrealistic I think the market cap could be $100,000,000 - $200,000,000 which would mean: $2.25 - $4.50.  
Let's hope this happens.
Comment by Humanist on Aug 05, 2022 4:34pm
ive been watching this stock for quite some time..   do you happen to know if there is a scheduled arbitration, court, etc... of any type between the 2 .. thx  sheseido is the the problem. and being such a shark of a company, you know how its big fish eat small fish.. so lets hope they settle something its been years glta
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities